Fidelity has four other funds listed on the INSM site. I recognize the Small Cap Opportunity from one I own. I think the big deferred annuity has a piece of that action also. I bought in last May. Guaranteed 5% rollout each month into a retirement account, can access the who investment after 5 years. Wanted $25,000 per year but it now is performing at $27,000 per year in 10 months.
The Shire-Premacure buyout has the opportunity to facilitate refocusing for the future use of Iplex. MGH is on the verge of recruiting for its Phase III, Anorexia Nervosa bone deficiency study for women using Increlex. The results of that study clearly showed that IGF-1 promoted bone regeneration in young women with the equivalent of malnutrition induced osteoporosis. From looking at Shire's pipeline and products, FOB is a totally new area for them. I think they are going to rely on Premacure and the funded plan for Sahlgrenska University Hospital to collaboratively establish a Premiplex production process at a contract facility. But IGF-1 also has the possibility for a totally unique in vitro use at Shire. They grow therapeutic fibroblasts in vitro for use in various dermatology conditions. We shall see, but probably not for a few years. I am hoping that they will pursue ALS and swallowing reflex protection.